Avidity Biosciences, Inc. (RNA)
Largest Insider Buys in Sector
RNA Stock Price History Chart
RNA Stock Performance
About Avidity Biosciences, Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Insider Activity of Avidity Biosciences, Inc.
Over the last 12 months, insiders at Avidity Biosciences, Inc. have bought $0 and sold $57.76M worth of Avidity Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Avidity Biosciences, Inc. have bought $18.45M and sold $16.2M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 800,000 shares for transaction amount of $14.4M was made by RTW INVESTMENTS, LP (10 percent owner) on 2021‑08‑04.
List of Insider Buy and Sell Transactions, Avidity Biosciences, Inc.
| 2024-12-18 | Sale | President and CEO | 31,855 0.0283% | $32.66 | $1.04M | -2.62% | ||
| 2024-12-18 | Sale | Chief Financial Officer | 11,151 0.0099% | $32.66 | $364,192 | -2.62% | ||
| 2024-12-18 | Sale | Chief Human Resources Officer | 11,151 0.0099% | $32.66 | $364,192 | -2.62% | ||
| 2024-12-18 | Sale | CSTO | 12,742 0.0113% | $32.66 | $416,154 | -2.62% | ||
| 2024-12-16 | Sale | Chief Human Resources Officer | 25,000 0.0208% | $33.26 | $831,605 | -8.22% | ||
| 2024-12-11 | Sale | CSTO | 24,000 0.0201% | $35.77 | $858,401 | -12.54% | ||
| 2024-11-19 | Sale | director | 3,323 0.0027% | $42.12 | $139,973 | -22.37% | ||
| 2024-11-18 | Sale | Chief Human Resources Officer | 25,000 0.02% | $41.14 | $1.03M | -18.36% | ||
| 2024-11-06 | Sale | Chief Financial Officer | 41,137 0.0368% | $45.92 | $1.89M | -21.93% | ||
| 2024-10-21 | Sale | director | 5,000 0.0045% | $46.63 | $233,168 | -10.36% | ||
| 2024-10-16 | Sale | Chief Human Resources Officer | 25,000 0.0236% | $48.52 | $1.21M | -13.73% | ||
| 2024-10-07 | Sale | director | 30,000 0.0263% | $44.98 | $1.35M | -1.66% | ||
| 2024-10-01 | Sale | CSTO | 62,500 0.058% | $47.62 | $2.98M | -10.84% | ||
| 2024-09-23 | Sale | President and CEO | 32,880 0.0282% | $44.00 | $1.45M | -0.39% | ||
| 2024-09-23 | Sale | Chief Financial Officer | 11,510 0.0099% | $44.00 | $506,440 | -0.39% | ||
| 2024-09-23 | Sale | CSTO | 25,000 0.0214% | $43.95 | $1.1M | -0.39% | ||
| 2024-09-23 | Sale | Chief Human Resources Officer | 13,153 0.0113% | $44.00 | $578,737 | -0.39% | ||
| 2024-09-19 | Sale | director | 5,000 0.0045% | $45.73 | $228,658 | -4.71% | ||
| 2024-09-11 | Sale | CSTO | 111,394 0.0877% | $40.40 | $4.5M | +6.88% | ||
| 2024-09-11 | Sale | Chief Human Resources Officer | 25,000 0.0197% | $40.40 | $1.01M | +6.88% |
Insider Historical Profitability
| Boyce Sarah | President and CEO | 265308 0.2224% | $28.36 | 0 | 20 | |
| MacLean Michael F | Chief Financial Officer | 82942 0.0695% | $28.36 | 0 | 8 | |
| McCarthy Teresa | Chief Human Resources Officer | 82867 0.0695% | $28.36 | 0 | 8 | |
| Flanagan W. Michael | CSTO | 72647 0.0609% | $28.36 | 0 | 7 | |
| LEVIN ARTHUR A | director | 14830 0.0124% | $28.36 | 0 | 27 | |
| Thompson Tamar | director | 0 0% | $28.36 | 0 | 1 | |
| RTW INVESTMENTS, LP | 10 percent owner | 4795000 4.019% | $28.36 | 2 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 2514545 2.1076% | $28.36 | 1 | 0 | <0.0001% |